Aerovate Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Jade Biosciences, Inc. disclosed its second-quarter 2026 financial results, highlighting increased research and development spending and general administrative costs, alongside positive interim clinical data for its lead candidates.
Jade Biosciences, Inc. reported increased operating expenses, particularly in research and development, for the first quarter of 2026, while maintaining a substantial cash and investment balance.
Jade Biosciences, a clinical-stage biopharmaceutical company, reported a net loss of $25.2 million for Q3 2025, while significantly enhancing its liquidity with a $135 million private placement completed in October 2025.
Jade Biosciences, Inc. reports a strong cash position of $220.9 million following a reverse recapitalization and pre-closing financing, enabling advancement of its autoimmune disease pipeline.
Aerovate Therapeutics reports Q1 2025 results, discontinues AV-101 program, and focuses on a merger with Jade Biosciences.
10-Q: Aerovate Therapeutics Announces Merger with Jade Biosciences Following Disappointing Trial Results
Aerovate Therapeutics will merge with Jade Biosciences after halting its Phase 3 trial for AV-101 due to negative results, and plans a significant cash dividend to pre-merger stockholders.
Aerovate Therapeutics has discontinued development of its lead drug candidate, AV-101, following disappointing Phase 2b trial results and is now exploring strategic alternatives.
Aerovate Therapeutics, a clinical-stage biopharmaceutical company, announced its first quarter 2024 financial results, highlighting ongoing clinical trial progress for its lead drug candidate, AV-101.